Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behçet's disease

Journal of Immunology

Volumn 190, Issue 11, 2013, Pages 5799-5808

  Sugita, Sunao ^a,b   Kawazoe, Yuko ^a   Imai, Ayano ^a   Kawaguchi, Tatsushi ^a   Horie, Shintaro ^a   Keino, Hiroshi ^c   Takahashi, Masayo ^b   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON ANTIBODY; GAMMA INTERFERON; INFLIXIMAB; INTERFERON ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6 ANTIBODY; RETINA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE UVEITIS; BEHCET DISEASE; BLOCKING FACTOR; CD4+ T LYMPHOCYTE; CELL LINE; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH22 CELL; UVEITIS;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKINS; MICE; RECEPTORS, CYTOKINE; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84878035694     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202677     Document Type: Article

References (30)

1. Raziuddin, S., A. al-Dalaan, S. Bahabri, A. K. Siraj, and S. al-Sedairy. 1998. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J. Rheumatol. 25: 329-333.
2. Hamzaoui, K., A. Hamzaoui, F. Guemira, M. Bessioud, M. Hamza, and K. Ayed. 2002. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand. J. Rheumatol. 31: 205-210. (Pubitemid 34971876)
3. Hamzaoui, K., E. Bouali, I. Ghorbel, M. Khanfir, H. Houman, and A. Hamzaoui. 2011. Expression of Th-17 and RORgt mRNA in Behçet's Disease. Med. Sci. Monit. 17: CR227-CR234.
4. Takeuchi, M., Y. Usui, Y. Okunuki, L. Zhang, J. Ma, N. Yamakawa, T. Hattori, T. Kezuka, J. Sakai, and H. Goto. 2010. Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. Invest. Ophthalmol. Vis. Sci. 51: 3067-3075.
5. Chi, W., X. Zhu, P. Yang, X. Liu, X. Lin, H. Zhou, X. Huang, and A. Kijlstra. 2008. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest. Ophthalmol. Vis. Sci. 49: 3058-3064.
6. Sugita, S., Y. Kawazoe, A. Imai, Y. Yamada, S. Horie, and M. Mochizuki. 2012. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res. Ther. 14: R99.
7. Mizuki, N., A. Meguro, M. Ota, S. Ohno, T. Shiota, T. Kawagoe, N. Ito, J. Kera, E. Okada, K. Yatsu, et al. 2010. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat. Genet. 42: 703-706.
8. Remmers, E. F., F. Cosan, Y. Kirino, M. J. Ombrello, N. Abaci, C. Satorius, J. M. Le, B. Yang, B. D. Korman, A. Cakiris, et al. 2010. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat. Genet. 42: 698-702.
9. Li, Z., B. Liu, A. Maminishkis, S. P. Mahesh, S. Yeh, J. Lew, W. K. Lim, H. N. Sen, G. Clarke, R. Buggage, et al. 2008. Gene expression profiling in autoimmune noninfectious uveitis disease. J. Immunol. 181: 5147-5157.
10. Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 10: 857-863.
11. Trifari, S., C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10: 864-871.
12. Eyerich, S., K. Eyerich, D. Pennino, T. Carbone, F. Nasorri, S. Pallotta, F. Cianfarani, T. Odorisio, C. Traidl-Hoffmann, H. Behrendt, et al. 2009. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 119: 3573-3585.
13. Sagawa, K., M. Mochizuki, K. Masuoka, K. Katagiri, T. Katayama, T. Maeda, A. Tanimoto, S. Sugita, T. Watanabe, and K. Itoh. 1995. Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis. Detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production. J. Clin. Invest. 95: 852-858.
14. Sugita, S., H. Takase, C. Taguchi, Y. Imai, K. Kamoi, T. Kawaguchi, Y. Sugamoto, Y. Futagami, K. Itoh, and M. Mochizuki. 2006. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest. Ophthalmol. Vis. Sci. 47: 2547-2554. (Pubitemid 351639840)
15. Caspi, R. R., F. G. Roberge, C. C. Chan, B. Wiggert, G. J. Chader, L. A. Rozenszajn, Z. Lando, and R. B. Nussenblatt. 1988. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140: 1490-1495.
16. Thurau, S. R., C. C. Chan, R. B. Nussenblatt, and R. R. Caspi. 1997. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin. Exp. Immunol. 109: 370-376. (Pubitemid 27308427)
17. Sfikakis, P. P., P. G. Theodossiadis, C. G. Katsiari, P. Kaklamanis, and N. N. Markomichelakis. 2001. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358: 295-296. (Pubitemid 32738970)
18. Muñoz-Fernández, S., V. Hidalgo, J. Fernández- Melón, A. Schlincker, and E. Martín-Mola. 2001. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 358: 1644. (Pubitemid 33101925)
19. Ohno, S., S. Nakamura, S. Hori, M. Shimakawa, H. Kawashima, M. Mochizuki, S. Sugita, S. Ueno, K. Yoshizaki, and G. Inaba. 2004. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J. Rheumatol. 31: 1362-1368. (Pubitemid 38879203)
20. Tugal-Tutkun, I., A. Mudun, M. Urgancioglu, S. Kamali, E. Kasapoglu, M. Inanc, and A. Gül. 2005. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum. 52: 2478-2484. (Pubitemid 41117435)
21. Tabbara, K. F., and A. I. Al-Hemidan. 2008. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am. J. Ophthalmol. 146: 845-850.e1.
22. Yamada, Y., S. Sugita, H. Tanaka, K. Kamoi, T. Kawaguchi, and M. Mochizuki. 2010. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br. J. Ophthalmol. 94: 284-288.
23. Yamada, Y., S. Sugita, H. Tanaka, K. Kamoi, H. Takase, and M. Mochizuki. 2011. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br. J. Ophthalmol. 95: 205-208.
24. Sugita, S., Y. Yamada, and M. Mochizuki. 2011. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br. J. Ophthalmol. 95: 549-552.
25. Ikeuchi, H., T. Kuroiwa, N. Hiramatsu, Y. Kaneko, K. Hiromura, K. Ueki, and Y. Nojima. 2005. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52: 1037-1046. (Pubitemid 40530109)
26. Sugimoto, K., A. Ogawa, E. Mizoguchi, Y. Shimomura, A. Andoh, A. K. Bhan, R. S. Blumberg, R. J. Xavier, and A. Mizoguchi. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118: 534-544. (Pubitemid 351206544)
27. Ma, H. L., S. Liang, J. Li, L. Napierata, T. Brown, S. Benoit, M. Senices, D. Gill, K. Dunussi-Joannopoulos, M. Collins, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118: 597-607. (Pubitemid 351206549)
28. Zhang, N., H. F. Pan, and D. Q. Ye. 2011. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol. Cell. Biochem. 353: 41-46.
29. Van Belle, A. B., M. de Heusch, M. M. Lemaire, E. Hendrickx, G. Warnier, K. Dunussi-Joannopoulos, L. A. Fouser, J. C. Renauld, and L. Dumoutier. 2012. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 188: 462-469.
30. Li, Z., A. R. Burns, S. B. Miller, and C. W. Smith. 2011. CCL20, γδ T cells, and IL-22 in corneal epithelial healing. FASEB J. 25: 2659-2668.